Related Experiment Videos
[Prenatal lung maturation with corticosteroids--an overview]
K Hildebrand1, I Hösli, W Holzgreve
1Universitätsfrauenklinik Basel, Schweiz.
Insights
Antenatal corticosteroids significantly reduce respiratory distress syndrome (RDS) complications in preterm infants. Combining corticosteroids with Thyrotropin Releasing Hormone (TRH) may further enhance lung maturity, but requires more clinical research.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Pulmonology
Context:
- Respiratory distress syndrome (RDS) is a major cause of mortality and morbidity in preterm infants.
- Antenatal corticosteroid administration has been a cornerstone in reducing neonatal complications since 1969.
- Understanding the pathophysiological effects of corticosteroids on neonatal outcomes is crucial.
Purpose:
- To review the pathophysiological effects of antenatal corticosteroids on neonatal outcomes.
- To explore the combined use of corticosteroids and Thyrotropin Releasing Hormone (TRH) for enhancing lung maturity.
- To highlight the need for further clinical investigation into combination therapy.
Summary:
- Antenatal corticosteroids are proven to reduce neonatal morbidity associated with RDS.
- Experimental data suggest that Thyrotropin Releasing Hormone (TRH) may potentiate corticosteroid effects, enhancing fetal lung maturation.
- Clinical evidence for the combined therapy is promising but requires further investigation.
Impact:
- Provides a comprehensive review of corticosteroid therapy for RDS prevention.
- Highlights a potential synergistic effect of TRH with corticosteroids for improved neonatal lung development.
- Informs future research directions, including an upcoming European multicenter trial for combination therapy.
Abstract:
Respiratory distress syndrome (RDS) and ist complications are a key factor affecting mortality and immediate and long-term morbidity in preterm babies. Since the observations of Liggins in 1969, numerous investigations have shown that antenatal corticosteroid administration reduces neonatal morbidity. In this review we summarize the known pathophysiological effects of this treatment and their impact on neonatal outcomes. In a second part we focus on the combination corticosteroids plus Thyrotropin Releasing Hormone (TRH). The additive use of TRH seems to potentiate corticosteroid effects enhancing lung maturity, as will be shown in an overview of experimental results. The interpretations of the clinical results however show a need for further investigations, which will be done in an European multicenter trial.